OPEN ACCESS

ORIGINAL ARTICLE

Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK

Georg Hansmann,¹ Christian Apitz²

For numbered affiliations see end of article.

Correspondence to

Prof. Dr. Georg Hansmann, FESC, FAHA, Department of Paediatric Cardiology and Critical Care, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany; georg.hansmann@gmail.com

This paper is a product of the writing group of the European Paediatric Pulmonary Vascular Disease (PVD) Network (Writing Group Chair: G. Hansmann, Writing Group Co-Chair: C. Apitz). ISHLT, International Society of Heart and Lung Transplantation; DGPK, German Society of Paediatric Cardiology.

Received 29 November 2015

Revised 6 January 2016

Accepted 18 January 2016

ABSTRACT

Treatment of children and adults with pulmonary hypertension (PH) with or without cardiac dysfunction has improved in the last two decades. The so-called pulmonary arterial hypertension (PAH)-specific medications currently approved for therapy of adults with PAH target three major pathways (endothelin, nitric oxide, prostacyclin). Moreover, some PH centres may use off-label drugs for compassionate use. Pulmonary hypertensive vascular disease (PHVD) in children is complex, and selection of appropriate therapies remains difficult. In addition, paediatric PAH/PHVD therapy is vastly based on experience and trial data from adult rather than paediatric studies; however, the first randomised paediatric PAH trials have been conducted recently. We present consensus recommendations for the treatment of children with PH. Class of recommendation and level of evidence were assigned based on paediatric data only or on adult studies that included >10% children. After a systematic literature search and analysis of the published data, we developed treatment strategies and algorithms that can guide goal-oriented PH therapy. We discuss early combination therapy (double, triple) in patients with PAH in functional class II–IV and in those with inadequate response to the initial pharmacotherapy. In those children with progressive, severe PAH and inadequate response, advances in drug development, and interventional and surgical approaches provide promising new strategies to avoid, reverse or ameliorate right heart failure and left ventricular compression. In particular, first follow-up data indicate that Potts shunt (left pulmonary artery to descending aorta anastomosis) may be an alternative destination therapy, or bridge to bilateral lung transplantation, in end-stage paediatric PAH.

INTRODUCTION

Pulmonary arterial hypertension (PAH) is still an important cause of morbidity and mortality in children. Despite recent developments in PAH-specific therapies, survival of patients with idiopathic PAH remains poor and appears to be worse in children compared with adults.¹ During the past few years, treatment of PAH has undergone a remarkable evolution, which has led to the current approval by regulatory agencies of 10 drugs for adult patients from three main pharmacological groups (addressing three pathways) and four different routes of

administration (oral, inhaled, subcutaneous and intravenous). Additional drugs are expected in the near future. Modern drug therapy improves the symptoms of PAH patients and slows down the rates of clinical deterioration. However, emerging therapeutic strategies for adult PAH, such as upfront oral combination therapy, have not been sufficiently studied in children. Moreover, the complexity of pulmonary hypertensive vascular disease (PHVD) in children makes the selection of appropriate therapies a great challenge far away from a mere prescription of drugs. Therapy of paediatric PH is rather characterised by a complex strategy that includes the evaluation of severity and prognosis of the individual disease, the estimation of efficacy of different drugs, and their interaction and combination, as well as supportive and general measures.

Recently, additional surgical and interventional techniques for palliation of children with severe PAH have been reported. The beneficial effects of these strategies are mainly based on the relief of right ventricle (RV) pressure overload with a subsequent reduction of the interventricular septum shift to the left ventricle (LV), and improvement of systolic and diastolic LV performance.

In this paper, we present a comprehensive overview of the current available drug-based and interventional/surgical treatments in paediatric PH and provide the recommendations of the European Paediatric Pulmonary Vascular Disease Network.

METHODS

The recommendations given in [table 1](#) relate to the grading system currently suggested by the European Society of Cardiology (ESC) and the American Heart Association, and were based on paediatric data only, or adult studies enrolling >10% children (class of recommendation, level of evidence). The grading and voting process within the writing group is outlined in the *executive summary*.² Computerised searches of the PubMed/MEDLINE bibliographic database were conducted between January 1990 and November 2015. Clinical trials, guidelines and reviews limited to paediatric data were searched using the terms ‘pulmonary hypertension’, ‘heart failure’, ‘pharmacotherapy’, ‘drugs’, ‘randomized controlled trial’, ‘atrial septostomy’

CrossMark

To cite: Hansmann G, Apitz C. *Heart* 2016;**102**:ii67–ii85.

Table 1 Recommendations on treatment of children with pulmonary hypertension

Recommendations	COR	LOE
Oxygen therapy is reasonable in patients with hypoxaemic PH who consistently have oxygen saturations < 92% or paO_2 <60 mm Hg	IIa	C
Inhalative oxygen can be particularly useful for patients with PH and an element of parenchymal lung disease (eg, bronchopulmonary dysplasia/nCLD)	IIa	B
Inhalative oxygen can be useful for patients with intrapulmonary shunt, and important for patients with PH while at altitude or during air travel	IIa	C
Based on PAH and heart failure studies in adults, <i>mineralocorticoid receptor blockade</i> with spironolactone can be beneficial in patients with PAH by improving right ventricle and left ventricle diastolic function, particularly in 'heart failure with preserved ejection fraction'	IIa	C
Diuretic therapy may be considered for selected paediatric patients with pulmonary hypertension	IIb	C
Diuretic therapy should be initiated cautiously since patients with PH/PPHVD are often pre-load dependent to maintain optimal cardiac output	I	C
The benefit of <i>chronic anticoagulation</i> (warfarin, phenprocoumon) in children with PAH is unclear (so far not studied in children)	IIb	C
Chronic anticoagulation can be useful in patients with progressive IPAH/HPAH (empirical goal INR 2.0–2.5), patients with CTEPH, patients with low cardiac output and those with hypercoagulable states	IIa	C
Indication for anticoagulation should be critically reviewed, especially in small children prone to haemorrhagic complications. In these cases, antiplatelet therapy (eg, ASA) may be an alternative	IIb	C
Anticoagulation is potentially harmful in children with hereditary haemorrhagic telangiectasia or portopulmonary hypertension	III harm	C
Before starting targeted PAH therapy for chronic PH/PPHVD, vasodilator responsiveness should be determined by cardiac catheterisation and anatomic obstruction from pulmonary venous disease or from left-sided heart disease should be excluded (see ref 16)	I	B
Calcium channel blockers (CCBs): A trial of CCB monotherapy should be pursued only in those patients who have previously been shown to be acutely reactive to $\text{iNO} \pm \text{oxygen}$, that is, those who have a positive AVR ('AVT responders')	IIa	C
For children with a negative AVR, or in those with a failed or non-sustained response to CCBs, risk stratification should probably determine additional targeted therapy	IIa	C
CCBs are contraindicated in children who have not undergone AVT, non-responders to acute vasodilator testing and in those with right heart failure, that is, WHO functional class IV, regardless of acute vasodilatory response (due to potential negative inotropic effect of CCB, especially in patients with low cardiac output)	III harm	C
The majority of children with severe PAH are non-responsive to acute vasodilator testing to $\text{iNO} \pm \text{oxygen}$ and require 'targeted' therapy other than CCBs	I	C
In the child with mild-to-moderate chronic PH/PPHVD and lower risk (figure 1), initiation of <i>oral goal-targeted therapy</i> is recommended (figures 2 and 3), regardless of a negative AVR, and should begin with either a PDE-5-inhibitor or an endothelin receptor antagonist	I	B
Oral <i>sildenafil</i> can be useful in the setting of iNO therapy withdrawal in postoperative PH or in the presence of PH related to chronic lung disease	IIa	B
High-dose oral sildenafil treatment (defined in the STARTS-1/-2 RCT, and table 2), either as monotherapy, or add-on drug, carries an unfavourable risk-to-benefit ratio in children (>8 kg, >1 year old) with PAH/PPHVD, including potentially increased mortality	III harm	B
Intravenous sildenafil can be advantageous in neonates with PPHN treated with or without iNO	IIa	C
In severe (WHO functional class IV) and/or rapidly progressive PAH/PPHVD (diagnosed by cardiac catheterisation and non-invasive imaging), continuous intravenous <i>prostacyclin analogue therapy</i> , that is, epoprostenol or treprostinil, should be started without delay (start with prostanoid monotherapy or dual/triple combination therapy including prostacyclin analogues)	I	C
Start of prostacyclin analogue therapy with intravenous treprostinil (COR IIa, C) or intravenous iloprost (COR IIa, C), instead of epoprostenol, may be considered in certain circumstances, given the advantage of longer plasma half-life and greater stability/ease of application for both treprostinil and iloprost (see main text and table 2, for indications and adverse effects)	IIa	C
Early combination therapy with two oral PAH drugs in newly diagnosed (treatment naive) children with PAH in WHO functional class II–III may be considered	IIb	C
Combination of intravenous (eg, epoprostenol, treprostinil) or subcutaneous prostacyclin analogues (treprostinil) with 1 or 2 oral PAH-targeted drugs (eg, sildenafil, bosentan) may result in better long-term survival in PAH	IIb	C
iNO is mainly used in the ICU setting and is useful in patients with acute pulmonary vascular crisis and/or acute exacerbation of PH in the setting of an underlying parenchymal lung disease and/or PPHN	I	B
Concomitant sildenafil should be administered to prevent rebound PH in patients who have signs of increased PAP on withdrawal of iNO and require restart of iNO despite preceding gradual weaning of iNO	I	B
Atrial septostomy can be considered in patients in functional class III and IV and recurrent syncope under combined medical therapy, and as palliative bridge to transplant increasing the chance for survival while waiting for a donor organ	IIb	C
Based on a small series of children with end-stage PAH, a surgical anastomosis between the left pulmonary artery and the descending aorta (<i>Potts shunt</i>) may be considered as valuable alternative (destination therapy) or bridge to bilateral lung transplantation in selected cases	IIb	C

The recommendations relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association, and were based on paediatric data only (class, level of evidence). The grading and voting process within the writing group is outlined in the executive summary² in this special issue. Recommendations on PH therapy specifically in neonatal chronic lung disease and persistent pulmonary hypertension of the newborn,⁵ and PAH associated with congenital heart disease,⁴ are outlined in separate articles in this special issue.

AVT, acute vasodilator testing; AVR, acute vasoreactivity response; CCB, calcium channel blockers; COR, class of recommendation; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; iNO , inhaled nitric oxide; INR, international normalised ratio; IPAH, idiopathic pulmonary arterial hypertension; LOE, level of evidence; PAH, pulmonary arterial hypertension; PDE5, phosphodiesterase 5; PH, pulmonary hypertension; PPHVD, Pulmonary hypertensive vascular disease; PPHN, persistent pulmonary hypertension of the newborn; RCT, randomised controlled trials

and 'Potts shunt', in multiple combinations. The primary focus of this paper is on pharmacotherapy and catheter-interventional/surgical treatment of group 1 PH (ie, PAH) according to the World Symposium PH classification, Nice 2013. Therapy of group 2–5 PH is controversial and requires separate discussions. Special considerations for the treatment of PH in the acute and critical care setting,³ treatment of PAH patients with congenital heart disease (CHD)⁴ and therapy of infants with PH associated

with acute and chronic lung disease (CLD)⁵ are discussed in separate articles of this special issue.

Pharmacotherapy

Drug therapy in pulmonary hypertension consists of so-called 'supportive' and 'PAH-specific' therapy (table 1). Detailed information on dosing, adverse effects and other information can be found in table 2.

Determinants of Risk in Paediatric Pulmonary Vascular Disease (PHVD)

Lower Risk	Determinants of Risk	Higher Risk
No	Clinical evidence of RV failure	Yes
No	Progression of symptoms	Yes
No	Syncope	Yes
	Growth	Failure to thrive
I,II	WHO functional class	III,IV
Minimally elevated	Serum BNP/ NT-proBNP	Significantly elevated Rising level
	Echocardiography	Severe RV enlargement/ RV dysfunction Pericardial effusion
CI >3.0 l/min/m ² mPAP/mSAP <0.5 Acute vasoreactivity	Hemodynamics	CI <2.5l/min/m ² mPAP/mSAP >0.75 mRAP >15 mm Hg PVRi >15 WU x m ²

Figure 1 Determinants of risk in paediatric pulmonary hypertensive vascular disease. The variables listed distinguish between lower risk and higher risk. The intermediate risk group is broad and not specifically defined. Overall, these determinants have only level of evidence C due to sparse or lacking paediatric data. Healthcare providers may include here pulmonary vascular resistance (PVR)/systemic vascular resistance (SVR) ratio, the 6 min walk distance and the max. oxygen consumption (VO₂ max.) obtained during cardiopulmonary exercise testing as risk variables; however, it is unclear where exactly the cut-off values should be set. One must also note that most of these variables have been validated mostly for idiopathic pulmonary arterial hypertension (IPAH) and the cut-off levels used above may not necessarily apply to other forms of pulmonary arterial hypertension (PAH). Furthermore, the use of approved therapies and their influence on the variables should be considered in the evaluation of the risk. Modified from McLaughlin *et al.*⁶ BNP, brain natriuretic peptide; CI, cardiac index (syn. Qs); mPAP, mean pulmonary artery pressure, mRAP, mean right atrial pressure; NT-proBNP, N terminal pro BNP; PVRi, PVR index; RA, right atrium; RV, right ventricle; SVRi, SVR index.

The overall goal of any PH therapy is the transition of a patient from the 'higher risk' to the 'lower risk' group⁶ (figure 1).

'Supportive' ('conventional') therapy

Therapies typically used for left heart failure have been also used for the treatment of patients with RV failure. Supportive therapy may include oxygen, anticoagulants, diuretics, mineral-corticoid receptor antagonists (spironolactone), digoxin. These measures are applied on an individual basis since the currently available studies provide either none or rather ambiguous/contradictory than valid data on most of these therapies in (adults and) children with PH.

Supplemental oxygen

Children with PH and pulmonary diffusion impairment, for example, infants with CLD/bronchopulmonary dysplasia, and those living with PH at high altitude, usually benefit from overnight or continuous oxygen supplementation to overcome chronic alveolar hypoxia. Long-term nocturnal oxygen supplementation improves symptoms in Eisenmenger patients but has not been shown to increase survival.⁸ Oxygen therapy is reasonable in patients with hypoxaemic PH who have oxygen saturations <92% and/or paO₂ <60 mm Hg. Any oxygen supplementation should result in a sustained rise in oxygen saturation and improvement of symptoms.

Diuretics (loop diuretics, thiazides)

Diuretic agents such as furosemide probably have been overused in patients with PAH. Diuretics should be initiated – if at all – cautiously as patients with PAH are frequently preload dependent to maintain sufficient cardiac output.

Digitalis

There are no sufficient clinical data to recommend or refuse the use of digoxin in adult or paediatric PAH patients with RV dysfunction,⁹ or overt right heart failure.

Mineralcorticoid receptor antagonists (spironolactone)

Spironolactone has only mild diuretic effects but blocks aldosterone and renin angiotensin aldosterone system signalling. RV remodelling and dysfunction appears to be responsive to MR blockade (spironolactone) in the ARIES-1/-2 trials.¹⁰ In a post hoc analysis of the ARIES-1/-2 trials, adult patients with PAH who received ambrisentan plus spironolactone had a better outcome than those who received ambrisentan alone.¹⁰ Most recently, both plasma aldosterone and its profibrotic target, galectin-3, were found to be increased in adult PAH and associated with WHO functional class, pointing to their role as potential tandem biomarkers.¹¹

Figure 2 Treatment algorithm for paediatric pulmonary arterial hypertension (PAH). This algorithm applies to idiopathic pulmonary arterial hypertension (IPAH) and hereditary PAH (HPAH (FPAH)). Solid clinical data on the therapy of other forms of PH are limited. The 'intermediate' risk group is broad and not specifically defined (see figure 1). Healthcare providers may consider upfront, early or rapid sequence targeted PAH therapy in 'intermediate' risk group (between 'lower risk' and 'higher risk' in figure 1: 'Determinants of risk'). Use of all agents is considered off-label in children aside from sildenafil and bosentan (>1 year old) in Europe. Sildenafil dosing recommendations should follow the European Medicines Agency-approved dosing for children. Bosentan received the following dual grading: class of recommendation (COR) I, level of evidence (LOE) B for children with PAH and Eisenmenger syndrome (E.S.), and COR IIa, LOE C for children with PAH without Eisenmenger syndrome. Modified and expanded from Ivy *et al.*⁷ CCB, calcium channel blocker; ERA, endothelin receptor antagonist; inh., inhalation; IV, intravenous; PDE-5i, phosphodiesterase 5 inhibitor; SC, subcutaneous.

Anticoagulation

A potential benefit of long-term anticoagulation (coumadin, warfarin) has not been studied in paediatric PAH, and its use in adults with PAH currently is the subject of an ongoing debate.¹² The role of the new oral anticoagulants (NOACs) in PAH is unknown. Thus, aspirin may be considered an alternative to coumadin or warfarin in paediatric idiopathic pulmonary arterial hypertension (IPAH)/hereditary pulmonary arterial hypertension (HPAH), particularly in younger, very active children with an assumed higher bleeding risk because of higher accident rates (table 2). The ESC/ERS guidelines for adult PH (2015) carefully outline that anticoagulants may be considered only in adult PAH patients with IPAH, HPAH and PAH associated with anoxigen use (class of recommendation IIb, level of evidence C).¹² The use of oral anticoagulants in Eisenmenger syndrome is controversial because the high incidence of PA thrombosis and stroke has to be balanced against the increased risk of haemorrhage and haemoptysis.^{13–14} Anticoagulation is potentially harmful in children with hereditary haemorrhagic telangiectasia¹⁵ or portopulmonary hypertension.

Many PH centres would recommend oral anticoagulation (coumadin, warfarin) in children with high-risk IPAH/HPAH (figures 1 and 2), paediatric PAH patients with low cardiac output, those with hypercoagulable conditions and/or those with long-term indwelling catheters (empiric international normalised

ratio (INR) goal 2.0–2.5; some centres recommend INR 1.5–2.0 in young children).

Routine vaccinations are generally recommended for children with PAH: especially infections with influenza, respiratory syncytial virus and pertussis, as well as pneumococcal infections, may lead to PH exacerbation and higher morbidity/mortality.¹⁶

For the following discussion of PAH-targeted pharmacotherapies and the according recommendations (tables 1 and 2), we focused the main text on paediatric PAH studies, adult studies that included at least 10% children and the most recent studies (2013–2015) on novel oral compounds (see methods in the executive summary).² The key outcome data of randomised controlled trials (RCTs) in adult PAH are summarised in tables 3–6.

Of note, most PAH-targeted medications are not approved by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for the use in children with PAH ('off-label' use).

Calcium channel blockers

Patients who fulfil the criteria of a positive response during acute vasoreactivity testing (AVT) are usually initially treated with an oral calcium channel blocker (CCB) (*amlodipine*, *nifedipine* or *diltiazem*) (table 2). In patients with IPAH/HPAH, the haemodynamic change that defines a positive

Figure 3 Treatment algorithm for combination therapy in pulmonary arterial hypertension (PAH) (evidenced-based only for adults with PAH, ie, group 1 PH). The 'intermediate' risk group is broad and not specifically defined (see figure 1). ^aSome WHO-FC III patients may be considered high risk (see figure 1, table 1). ^bIn adult PAH, initial combination with ambrisentan plus tadalafil has been shown to be superior to initial monotherapy with ambrisentan or tadalafil in delaying clinical failure. ^cIntravenous epoprostenol should be prioritised as it has reduced the 3 months rate for mortality in high-risk adult patients with PAH also as monotherapy. ^dConsider also balloon atrial septostomy or Potts shunt. Modified from Galie *et al.*¹² CCB, calcium channel blockers; DPAH, drug-induced PAH; HPAH, heritable PAH; IPAH, idiopathic PAH; IV., intravenous; PCA, prostacyclin analogues; WHO-FC, WHO functional class.

response to AVT (acute vasoreactivity response (AVR)) in PAH without a shunt (ratio of pulmonary to systemic flow (Qp:Qs) =1:1) for children should be considered as a >20% fall in mean pulmonary artery pressure (PAP) and pulmonary vascular resistance index (PVRi)/systemic vascular resistance index (SVRi) ratio without a decrease in cardiac output ('AVR in IPAH/HPAH').¹⁷ In the presence of a positive AVR, a fall of the ratio of PVRi/SVRi (or as the authors suggest alternatively, the ratio of the diastolic PAP/diastolic SAP) below 0.4 during the AVT might be an indication for calcium-channel blocker therapy.^{17 18} Of note, the above definition of a positive AVR was designed for the assessment of prognosis and indication for CCB therapy, but not for decision-making on shunt closure in PAH-CHD with elevated PVR.^{4 17}

Children with PAH associated with CHD and a significant left-to-right shunt (non-repaired CHD), and those with Eisenmenger syndrome (ie, suprasystemic PVR and right-to-left shunt) most likely do not benefit from CCB therapy.¹⁹ It is of great importance to evaluate and reassess the AVT response in children with PAH.¹⁷ When the conventional definition of positive AVT (Barst criteria) is applied to the REVAL study, 35% of IPAH/HPAH children but only 15% of those with PAH-CHD were vasoreactive, indicating that children with repaired CHD are less likely to respond during AVT.^{20 21}

Children with IPAH who responded to AVT had a survival of 97%, 97% and 81% at 1, 5 and 10 years, respectively; sustained treatment success with CCB was observed, but declined from 84% to 47% in the first 10 years after start of CCB therapy.²² Inadequate use of CCBs in paediatric PAH was associated with higher mortality: children with IPAH who were treated with a CCB regardless of their negative response during AVT had lower survival rates of 45%, 34%, 29% and 29% at 1, 2, 3 and 4 years, respectively.^{22 23}

CCBs are contraindicated in non-responders, patients with RV failure (WHO functional class IV)¹⁶ regardless of the AVT response, and those who have not undergone AVT.²⁴ The CCBs with significant negative inotropic effects (ie, non-dihydropyridines: *verapamil*, *diltiazem*) are usually not recommended for use in the first year of life. However, particularly diltiazem can have additional benefit in children with high heart rates because of its negative chronotropic/dromotropic effects, allowing longer filling and ejection times.

For children with a negative AVT or non-sustained response to CCB, PAH-targeted therapy via oral, inhalative and/or intravenous agents is required (see below). PAH-targeted therapy is currently predominantly based on three major pathways, the NO/cGMP pathway, the endothelin pathway and the prostacyclin pathway.

Table 2 Pharmacotherapy for paediatric PH

Agent	Indication	Dosing	Expected benefit	Possible side effects	COR/LOE comments
<i>Calcium channel blockers</i>					
Amlodipine	<ul style="list-style-type: none"> ▶ Only if reactive to vasodilator testing ▶ Do not use in patients with high right atrial pressure or low cardiac output 	<ul style="list-style-type: none"> ▶ Starting dose: 0.1 mg/kg/dose (or 1–5 mg/ adult dose), twice daily orally, uptitrate ▶ Maintenance dose: 2.5–10 mg/dose twice daily orally ▶ Max. adult dose 20 mg/day orally 	▶ Decrease in PVR	<ul style="list-style-type: none"> ▶ Bradycardia ▶ Decreased cardiac output ▶ Peripheral oedema ▶ Rash ▶ Gum hyperplasia ▶ Constipation 	COR I LOE B ▶ Duration of benefit may be limited even with initial favourable response ▶ Efficacy in Eisenmenger syndrome is rare
Nifedipine	<ul style="list-style-type: none"> ▶ Only if reactive to vasodilator testing ▶ Do not use in patients with high right atrial pressure or low cardiac output 	<ul style="list-style-type: none"> ▶ Starting dose 0.2–0.3 mg/kg/dose three times daily orally, uptitrate ▶ Maintenance dose: 1–2.5 mg/kg/dose twice daily orally ▶ Max. adult dose 120–240 mg/day orally in 3 divided doses ▶ May use extended release preparations (max. 180 mg/day orally) 	▶ Decrease in PVR	<ul style="list-style-type: none"> ▶ Bradycardia ▶ Decreased cardiac output ▶ Peripheral oedema ▶ Rash ▶ Gum hyperplasia ▶ Constipation 	COR I LOE B ▶ Duration of benefit may be limited even with initial favourable response ▶ Efficacy in Eisenmenger syndrome is rare
Diltiazem	<ul style="list-style-type: none"> ▶ Only if reactive to vasodilator testing ▶ Do not use in patients with high right atrial pressure or low cardiac output ▶ Use in neonates and infants is controversial 	<ul style="list-style-type: none"> ▶ Starting dose 0.5–0.7 mg/kg/dose three times daily orally, uptitrate ▶ Maintenance dose: 1–1.7 mg/kg/dose three times daily orally ▶ Max. adult dose 240 mg—360 mg/day orally in 3 divided doses Use extended release preparations (max. 360 mg/day orally) only once an effective short-acting dose is tolerated	▶ Decrease in PVR	<ul style="list-style-type: none"> ▶ Bradycardia ▶ Decreased cardiac output ▶ Peripheral oedema ▶ Rash ▶ Gum hyperplasia ▶ Constipation 	COR I LOE B ▶ Duration of benefit may be limited even with initial favourable response ▶ Efficacy in Eisenmenger syndrome is rare ▶ May cause bradycardia more than other CCB ▶ Suspension useful in younger children
<i>Phosphodiesterase type 5 inhibitors</i>					
Sildenafil	<ul style="list-style-type: none"> ▶ Approved for adult PH Group 1 ▶ EMA approved for paediatric PH Group 1 (age>1 year) ▶ FDA warning (2012) and subsequent clarification (2014) 	<p><i>Oral:</i></p> <ul style="list-style-type: none"> ▶ Starting dose: 0.3–0.5 mg/kg/dose three (eg, >1 year old) or four times (eg, <1 year old) daily orally ▶ Maintenance dose: 0.5–1 mg/kg/dose three (>1 year old) or four times (<1 year old) daily orally ▶ <8 kg (<i>no RCT data</i>) Starting dose 0.3–0.5 mg/kg/dose four times daily orally Maintenance dose: 1 mg/kg/dose four times daily orally. Maximum dose (controversial): 10 mg/dose orally three to four times daily (children) ▶ <i>European dosing (EMA approved):</i> 8–20 kg: 10 mg/dose three times daily orally (less in neonates/infants < 10 kg) ≥20 kg: 20 mg/dose three times daily orally <p><i>Intravenous:</i></p> 0.4 mg/kg bolus over 3 hours intravenous (optimal), then 1.6–2.4 mg/kg/d continuous intravenous infusion; do not exceed 30 mg/d	<ul style="list-style-type: none"> ▶ Increase in CI ▶ Decrease in PVR ▶ May improve diastolic ventricular function in single and biventricular circulations based on preclinical studies 	<ul style="list-style-type: none"> ▶ Flushing ▶ Agitation ▶ Hypotension ▶ Vision and hearing loss are concerning findings in premature infants ▶ Priapism 	COR I LOE B (COR III, LOE B for high dose) ▶ 1 paediatric RCT (STARTS-1/-2) ^{39 40} ▶ A greater mortality was noted in the STARTS-2 extension study in treatment naïve children treated with high dose sildenafil monotherapy ▶ <i>STARTS-1/-2 medium dosing regimen with best effect on VO₂ max was:</i> 8–20 kg, >1year old: 10 mg/dose three times daily orally, 20.1–45 kg: 20 mg/dose three times daily orally >45 kg 40 mg/dose orally three times daily ▶ FDA warning (2012) and subsequent clarification (2014) of chronic use in children 1–17 years old ▶ concomitant use of CYP3A4 inhibitors decreases clearance of sildenafil ▶ co-administration of bosentan leads to decreased sildenafil concentrations and increased bosentan concentrations (clinical relevance is unclear though) ▶ Use in premature neonates not well studied
			Higher Sildenafil doses up to 7.2 mg/kg/d intravenous have been used in newborn infants with PPHN associated with congenital diaphragmatic hernia		

Continued

Table 2 Continued

Agent	Indication	Dosing	Expected benefit	Possible side effects	COR/LOE comments
Tadalafil	<ul style="list-style-type: none"> Approved for adult PH Group 1 by the EMA and the FDA in 2009 	<ul style="list-style-type: none"> Starting adult dose: 20 mg/dose once daily orally Consider up-titration from 20 to 40 mg/dose once daily orally Max. adult dose: 40 mg/dose once a day orally Paediatric maintenance dose probably 1 mg/kg/day orally 	<ul style="list-style-type: none"> Increase in CI Decrease in PVR 	<ul style="list-style-type: none"> Side effects similar to sildenafil. Probably no significant effect on vision 	COR I LOE B <ul style="list-style-type: none"> Once a day dosing Safety and efficacy data in children are limited
<i>Guanylate Cyclase stimulators</i>					
Riociguat	<ul style="list-style-type: none"> Approved by the EMA and the FDA for adult PH Group 1 in 2014: (IPAH/HPAH only) and Group 4 PH (CTEPH) for monotherapy or combination therapy with ERA 	<ul style="list-style-type: none"> Starting adult dose 1 mg three times daily orally, up-titration required Maintenance adult dose 1–2.5 mg (dose three times daily orally) Maximum adult dose 2.5 mg/dose three times daily No published data on paediatric dosing in 2015 	<ul style="list-style-type: none"> Increase in CI Decrease in PVR 	<ul style="list-style-type: none"> Systemic arterial hypotension Headache, dizziness, dyspepsia Do not use together with PDE5-inhibitors (sildenafil, tadalafil) 	COR IIb LOE C <ul style="list-style-type: none"> Safety and efficacy data in children not available in 2015. COR I, LOE A for adult PH groups 1 and 4
<i>ERA</i>					
Bosentan (dual ET _A and ET _B receptor antagonist)	<ul style="list-style-type: none"> Approved by the EMA and the FDA for adult PH Group 1 Approved by the FDA and the EMA for use in children >1 years old For patients over 12 years old, benefit also shown for functional class II 	<ul style="list-style-type: none"> Starting dose: 0.3–1 mg/kg/dose twice daily, up-titration <10 kg: max. 2 mg/kg/dose twice daily orally 10–20 kg: max. 2 mg/kg/dose twice daily orally (32 mg tablets) 20–40 kg: 62.5 mg/dose twice daily orally > 40 kg: 125 mg/dose twice daily orally 	<ul style="list-style-type: none"> Increase in CI Decrease in PVR 	<ul style="list-style-type: none"> Abdominal pain, vomiting, extremity pain, fatigue, flushing, headache, oedema, nasal congestion, anaemia. Not recommended in patients with moderate or severe hepatic impairment Monthly LFTs required Incidence of AST/ALT elevation is less in children (3.5%) compared with adults Fluid retention Teratogenicity and male infertility are risks 	COR IIa, LOE C. For Eisenmenger: COR I, LOE B <ul style="list-style-type: none"> Data have been published on efficacy in Eisenmenger PH Caution in concomitant use of CYP3A4 inducers and inhibitors
Macitentan (dual ET _{1A} and ET _{1B} receptor antagonist)	<ul style="list-style-type: none"> Approved by the EMA and the FDA for adult PH Group 1 (IPAH/HPAH only) 	<ul style="list-style-type: none"> Starting dose (adults): 5–10 mg once daily orally Maintenance adult dose 10 mg once daily orally No published data on paediatric dosing in 2015 	<ul style="list-style-type: none"> Increase in CI Decrease in PVR 	<ul style="list-style-type: none"> Class-specific side effects are similar to bosentan Headache, nasopharyngitis, anaemia Not recommended in patients with moderate or severe hepatic impairment Dependent oedema may limit usefulness Teratogenicity and male infertility are risks (decreases in sperm count have been observed) 	COR IIb LOE C <ul style="list-style-type: none"> RCTs in adults (SERAPHIN)³³ Safety and efficacy data in children not available in 2015 Caution in concomitant use of CYP3A4 inducers and inhibitors

Continued

Table 2 Continued

Agent	Indication	Dosing	Expected benefit	Possible side effects	COR/LOE comments
Ambrisentan (selective ET _A receptor antagonist)	<ul style="list-style-type: none"> ▶ Approved for adult PH Group 1 by the FDA and the EMA ▶ Use in paediatrics has not been extensively evaluated ▶ In children >12 years old with intolerance to bosentan, there may be benefit 	<ul style="list-style-type: none"> ▶ Adult dosing starts with 5 mg daily up to 10 mg daily 	<ul style="list-style-type: none"> ▶ Increase in CI ▶ Decrease in PVR 	<ul style="list-style-type: none"> ▶ Class-specific side effects are similar to bosentan ▶ Incidence of serum aminotransferase elevation is low ▶ May decrease effectiveness of birth control ▶ Dependent oedema may limit usefulness ▶ Teratogenicity and male infertility are risks ▶ No drug–drug interactions between ambrisentan and sildenafil or tadalafil observed 	COR IIa LOE C <ul style="list-style-type: none"> ▶ Safety and efficacy data in children are limited ▶ Caution in concomitant use of CYP3A4 inducers and inhibitors
<i>Prostacyclin analogues (prostanoids)</i>					
Epoprostenol	<ul style="list-style-type: none"> ▶ Approved by the EMA and the FDA for adult PH Group 1 	Intravenous infusion <ul style="list-style-type: none"> ▶ Starting dose: 1–2 ng/kg/min intravenous without a known maximum ▶ Maintenance dose: 10–20–50–100 ng/kg/min intravenous ▶ In paediatric patients a stable dose is usually between 50 and 80 ng/kg/min intravenous at 1 year after start of treatment ▶ Doses > 150 ng/kg/min I intravenous have been used ▶ Dose increases are required ▶ High output failure at high doses can occur 	<ul style="list-style-type: none"> ▶ Increase in CI ▶ Decrease in PVR ▶ Increased survival 	<ul style="list-style-type: none"> ▶ Flushing, jaw, foot and bone pain, headaches and diarrhoea ▶ Systemic hypotension is possible ▶ The half-life is short (2–5 min) so PH crises occur rapidly if the infusion is stopped ▶ Ice pack cooling and remixing every 24 h needed ▶ Central line complications (infection, occlusion, extravasation) occur 	COR I LOE B <ul style="list-style-type: none"> ▶ Standard therapy for severe PH (WHC FC class IV) ▶ A 'temperature stable' formulation is now available
Trepstinil	<ul style="list-style-type: none"> ▶ Approved by the EMA the and FDA for adult PH Group 1 	Intravenous or subcutaneous infusion <ul style="list-style-type: none"> ▶ Starting dose 1–2 ng/kg/min without a known maximum ▶ In paediatric patients, a stable dose is usually met between 50 and 80 ng/kg/min intravenous/subcutaneous at 1 year ▶ Tolerance occurs and dose increases are required initially Inhalation (nebuliser, inhaler) <ul style="list-style-type: none"> ▶ 1–9 patient activated breaths every 6 h 	<ul style="list-style-type: none"> ▶ Increase in CI ▶ Decrease in PVR ▶ Improved or unchanged 1-year functional class ▶ Less severe side effects than epoprostenol 	<ul style="list-style-type: none"> ▶ Flushing, jaw, foot and bone pain, headaches and diarrhoea are common side effects that reoccur after each dose increase ▶ The frequency and severity of side effects are less than with epoprostenol ▶ Elimination half-life is 4.5 h with distribution half-life of 40 min ▶ The drug is stable at room temperature so it does not require cooling ▶ Central line complications (infection, occlusion, extravasation) can occur ▶ Subcutaneous injection site pain and possible infection limits this route ▶ Inhaled drug can worsen reactive airway symptoms 	For intravenous / subcutaneous: COR IIa, LOE C (intravenous), COR IIb, LOE C (subcutaneous) <ul style="list-style-type: none"> ▶ Safety and efficacy data in children are limited For intermittent inhalation: COR IIb LOE C <ul style="list-style-type: none"> ▶ The nebuliser requires patient activation and controlled inhalation limited by age and development

Continued

Table 2 Continued

Agent	Indication	Dosing	Expected benefit	Possible side effects	COR/LOE comments
Iloprost	► Approved adult for PH Group 1	Intravenous infusion <ul style="list-style-type: none"> ► Paediatric dosing has not been determined ► Intravenous infusion ► Starting dose: 1 ng/kg/min intravenous, uptitrate ► Maintenance dose 5–10 ng/kg/min intravenously as tolerated. A maximum intravenous dose has not been described. Inhalation (nebuliser, inhaler) <ul style="list-style-type: none"> ► Nebuliser for children (< ca. 5 years) and small inhaling devices for older children ► Paediatric dosing has not been determined but 6–9 inhalations per day are required, each lasting 8–15 min ► Start with 2.5 µg/dose (1.25 µg in small children) and uptitrate to 5 µg/dose as tolerated ► Dose range: Ampules deliver 2.5–5 µg to the mouth piece 	<ul style="list-style-type: none"> ► Improved CI ► Improved PVR 	<ul style="list-style-type: none"> ► Intravenous infusion (rarely used): similar to epoprostenol and treprostinil ► for inhalation: jaw pain, wheezing; especially at the initiation of therapy ► a new chip for the adaptive aerosol delivery systems allows now to reduce the duration of inhalations from 10–15 down to 4–5 min 	<ul style="list-style-type: none"> ► For intravenous infusion: COR IIb LOE C ► In paediatrics, the dosing frequency is not established <i>For intermittent inhalation</i> COR IIa LOE C <ul style="list-style-type: none"> ► In paediatrics, the dosing frequency and lack of compliance may limit its use ► Many experts recommend every 3 h inhalations during the day time for better compliance that can be recorded and monitored with a chip within the inhaler
Selexipag (oral use)	<ul style="list-style-type: none"> ► Prostacyclin IP receptor agonist ► Pending approval for adult PH group 1 (PAH) ► No paediatric data 	<ul style="list-style-type: none"> ► Adult dosing: ► Starting dose: 200 µg orally twice daily. Dosing increase in 200 µg twice daily steps ► Max. dose 1.6 mg twice daily orally 	<ul style="list-style-type: none"> ► Reduction of morbidity/mortality event. ► Improved CI ► Improved PVR 	<ul style="list-style-type: none"> ► To be determined (RCT and postmarketing surveillance pending) 	COR IIb LOE C GRIPHON trial (1156 PAH patients) ⁷¹ Significant risk reduction of morbidity/mortality events
<i>MR antagonists</i>					
Spironolactone	<ul style="list-style-type: none"> ► Improves hepatic congestion and oedema ► Inhibits MR and may improve RV and LV diastolic dysfunction 	<ul style="list-style-type: none"> ► Loop diuretics, thiazides and spironolactone are all dosed by weight and not differently than for other forms of heart failure 	<ul style="list-style-type: none"> ► Decreased signs of right heart failure 	<ul style="list-style-type: none"> ► Hyperkalaemia 	COR IIa LOE C <ul style="list-style-type: none"> ► Better outcome of adult PAH patients in post hoc analysis with add-on spironolactone to ambrisentan (ARIES-1/-2) ► Better outcome in adult patients with LV failure with preserved ejection fraction (HFpEF; LV diastolic dysfunction). A similar benefit was noted for the oral MR antagonist eplerenone in HFpEF
<i>Diuretics</i>					
Furosemide (loop diuretic)	<ul style="list-style-type: none"> ► May improve hepatic congestion and oedema. 	<ul style="list-style-type: none"> ► Loop diuretics, thiazides and spironolactone are all dosed by weight and not differently than for other forms of heart failure 	<ul style="list-style-type: none"> ► Decreased signs of right heart failure ► May be overused in PAH 	<ul style="list-style-type: none"> ► Caution: moderate to excessive diuresis can reduce the preload of the failing RV and worsen clinical status 	COR IIb LOE C
Hydrochlorothiazide (thiazide)	<ul style="list-style-type: none"> ► Improves hepatic congestion and oedema 	<ul style="list-style-type: none"> ► Loop diuretics, thiazides and spironolactone are all dosed by weight and not differently than for other forms of heart failure 	<ul style="list-style-type: none"> ► Decreased signs of right heart failure 	<ul style="list-style-type: none"> ► Care is needed as over diuresis can reduce the preload of the failing RV 	COR IIb LOE C

Continued

Table 2 Continued

Agent	Indication	Dosing	Expected benefit	Possible side effects	COR/LOE comments
<i>Inhalative therapies other than prostanooids</i>					
Oxygen	<ul style="list-style-type: none"> Helpful for cyanotic patients with an element of CLD or intrapulmonary shunt 	<ul style="list-style-type: none"> 1–2 L/min by nasal prongs 	<ul style="list-style-type: none"> Improved sense of well-being 	<ul style="list-style-type: none"> Too high a flow rate can dry the nares and cause epistaxis or rhinitis 	COR I LOE C <ul style="list-style-type: none"> Oxygen is not usually prescribed for children with PH unless the day time saturations are low (<92%) Polysomnography helpful in delineating the need for O₂ therapy at night Oxygen with sleep for sleep disordered breathing with SaO₂ decreasing to < 92% even if only transient Oxygen with exertion for patients with clinically significant desaturation with exertion
Nitric oxide (continuous inhalation)	<ul style="list-style-type: none"> PPHN Acute exacerbation of PAH, including PH crisis Acute PH in respiratory distress syndrome 	<ul style="list-style-type: none"> 0–5 ppm 20 ppm 	<ul style="list-style-type: none"> Selective fall in PVR 	<ul style="list-style-type: none"> Methaemoglobin and NO₂ at higher doses Rebound PH on weaning off iNO (risk can be reduced by concomitant use of sildenafil) 	COR IIa (PPHN), COR IIb (postop), LOE B Not approved by the EMA or the FDA for postoperative CHD
<i>Anticoagulative and antiplatelet agents</i>					
Coumadin, warfarin, phenprocoumon (vitamin K antagonists)	<ul style="list-style-type: none"> No definitive studies in children Oral anticoagulation in patients with a history of thrombosis, hypercoagulation, central lines Some PH centres use coumadin or warfarin in paediatric IPAHA or HPAH 	<ul style="list-style-type: none"> Individual dosing depends on agent used, co-medication, patient history Goal INRs in the range of (1.5-) 2.0–2.5 are usually chosen for this indication. Higher INR may be needed for history of thrombosis or hypercoagulability 	<ul style="list-style-type: none"> Prevention thrombosis and thromboembolic events 	<ul style="list-style-type: none"> The risk of anticoagulation in paediatrics must be balanced with the hypothetical benefits Teratogenic effects 	<ul style="list-style-type: none"> For IPAHA/HPAH: COR IIb LOE C For APAH: COR IIb LOE C Use of coumadin in children prior to walking well and in children may add risk
Acetylsalicylic acid (ASA; aspirin)	<ul style="list-style-type: none"> Alternative to oral anticoagulation (warfarin, coumadin) in paediatric IPAHA/HPAH, especially in small/active children 	<ul style="list-style-type: none"> Maintenance dose 2–4 mg/kg/dose once daily orally; max. 100 mg/dose Adult dose: 100 mg/dose once daily orally 	<ul style="list-style-type: none"> Inhibition of platelet aggregation, thrombosis and thromboembolic events 	<ul style="list-style-type: none"> Usual risks for ASA: bleeding, Reye syndrome, asthma Combination with clopidogrel or vitamin K antagonist carries moderate to high bleeding risk 	COR IIb LOE C
Contraceptives	<ul style="list-style-type: none"> Pregnancy in women with moderate-to-severe PH bares a high risk of maternal and fetal death Endothelin receptor antagonists are teratogenic Bosentan use requires two separate methods of contraception 	<ul style="list-style-type: none"> Non-oestrogen containing formulations are best Barrier methods may be effective 	<ul style="list-style-type: none"> Prevention of pregnancy and associated morbidity/mortality 		COR I LOE C

COR and LOE grading (higher than COR IIb and LOE C) is based on paediatric data only (or adult RCTs that included >10% children).

ALT, alanine aminotransferase; APAH, pulmonary arterial hypertension associated with disease; AST, aspartate aminotransferase; CCB, calcium channel blocker; CHD, congenital heart disease; COR, class of recommendation; CLD, chronic lung disease; EMA, European Medicines Agency; ERA, endothelin receptor antagonist; ET, endothelin; FDA, US Food and Drug Administration; HCT, haematocrit; HFpEF, patients with heart failure and preserved ejection fraction; HPAH, heritable pulmonary arterial hypertension; iNO, inhaled nitric oxide; INR, international normalised ratio; IPAHA, idiopathic pulmonary arterial hypertension; LFT, liver function test; LOE, level of evidence; LV, left ventricle; MR, mineralcorticoid receptor; PDE5, phosphodiesterase type 5; PH, pulmonary hypertension; PPHN, persistent pulmonary hypertension of the newborn; PVR, pulmonary vascular resistance; RCT, randomised controlled trial; RV, right ventricular; STARTS, Sildenafil in Treatment-Naive Children, Aged 1–17 Years, with Pulmonary Arterial Hypertension.

Table 3 Characteristics of RCTs with PAH drugs interfering with the endothelin pathway (endothelin receptors antagonists)

Drug(s) tested	Study	Patients number	Duration (weeks)	Background Therapy	Primary end point	Main results
Ambrisentan	ARIES-1 ³⁴	202	12	No	6MWD	6MWD improved TTCW not improved
	ARIES-2 ³⁴	192	12	No	6MWD	6MWD improved TTCW improved
Bosentan	Study-351 ³⁵	32	12	No	6MWD	6MWD improved TTCW improved
	BREATHE-1 ³⁶	213	16	No	6MWD	6MWD improved TTCW improved
	EARLY ³⁷	185	24	No Sildenafil (16%)	PVR, 6MWD	PVR improved TTCW improved 6MWD not improved
	BREATHE-5 ²⁹	54	12	No	SaO ₂ , PVR	PVR improved 6MWD improved
	COMPASS-2 ³⁸	334	99	Sildenafil	TTCW	TTCW not improved 6MWD improved NT-proBNP improved
Macitentan	SERAPHIN ³³	742	115	No or sildenafil or inhalative iloprost	TTCW	TTCW improved in monotherapy and in combination

Modified from Galie N *et al.*¹²

Note that most of the listed RCT data were derived from studies in adults with PAH. Healthcare providers must obtain valid information on the approval of any of the listed medications for use in paediatric PAH in the according country.

6MWD, 6 min walk distance; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; RCT, randomised controlled trial; SaO₂, finger oxygen saturation; TTCW, time to clinical worsening.

Endothelin-1 receptor antagonists

Bosentan

Activation of the endothelin system has been demonstrated in patients with PAH, whereas endothelin has vasoconstrictor and mitogenic effects. Bosentan is an oral, dual endothelin A-receptor and B-receptor antagonist (ERA for ET_A and ET_B). Multiple RCTs on bosentan in adults with PAH (idiopathic,

associated with CHD and CTD) showed improvement in exercise capacity, functional class, haemodynamics, echocardiographic variables and time to clinical worsening.

Retrospective observational studies and case series demonstrated that bosentan therapy is safe and appears to be effective in slowing disease progression children with PAH.^{25 26} A retrospective study of 86 children treated with bosentan with or

Table 4 Characteristics of RCTs with PAH drugs interfering with the nitric oxide pathway (soluble guanylate cyclase stimulators, phosphodiesterase type-5 inhibitors)

Drug(s) tested	Study	Patients number	Duration (weeks)	Background Therapy	Primary end point	Main results
Riociguat	PATENT ⁴⁵	443	12	No or bosentan or prostanoids	6MWD	6MWD improved Haemodynamics improved
	PATENT plus ⁴⁷	30	18	Sildenafil	Supine SBP	Terminated for excess of SAE in the treated group
Sildenafil	SUPER-1 ⁴⁸	277	12	No	6MWD	6MWD improved TTCW not improved
	Sastry ⁴⁹	22	12	No	TT	TT improved
	Singh ⁵⁰	20	6	No	6MWD	6MWD improved
	PACES ⁵¹	264	16	Epoprostenol	6MWD	6MWD improved TTCW and haemodynamics improved
	Iversen ⁵²	20	12	bosentan	6MWD	6MWD not improved
Sildenafil (paediatric)	Pfizer study A1481243	103	12	bosentan	6MWD	6MWD not improved
	STARTS-1 ³⁹	235	16	No	TT	%change in VO ₂ max, functional class and hemodynamic improved with medium and high doses
	STARTS-2 ⁴⁰	206	208	No	Survival	Survival improved
Tadalafil	PHIRST ⁵³	405	16	No or bosentan (54%)	6MWD	6MWD improved (in bosentan treated patients +23 m, 95% CI -2 to 48 m) TTCW improved
Vardenafil*	EVALUATION ⁵⁴	66	12	No	6MWD	6MWD improved TTCW improved

Modified from Galie N *et al.*¹²

Note that most of the listed RCT data were derived from studies in adults with PAH. Healthcare providers must obtain valid information on the approval of any of the listed medications for use in paediatric PAH in the according country.

*This drug is not approved by the EMA for use in adult PAH at the time of submission of this manuscript.

6MWD, 6 min walk distance; EMA, European Medicines Agency; PAH, pulmonary arterial hypertension; RCT, randomised controlled trial; TTCW, time to clinical worsening; TT, treadmill test.

Table 5 Characteristics of RCTs with PAH drugs interfering with the prostacyclin pathway (prostacyclin analogues and prostacyclin receptors agonists)

Drug(s) tested	Study	Patients number	Duration (weeks)	Background Therapy	Primary end point	Main results
Epoprostenol	Barst ⁶⁸	116	52	No	CW	CW not improved
	Rubin ⁷²	23	12	No	6MWD	6MWD improved Haemodynamics improved
	Barst ¹³	81	12	No	6MWD	6MWD improved Haemodynamics improved Survival improved
Treprostinil	Badesch ⁷³	111	12	No	6MWD	6MWD improved
	Subcutaneous—pivotal study ⁷⁴	470	12	No	6MWD	6MWD improved Haemodynamics improved Pain at infusion site
	Inhalative* TRIUMPH ⁷⁵	235	12	Bosentan or sildenafil	6MWD	6MWD improvement (+20 m at peak, +12 m at trough) TTCW not improved
	Orally*—Freedom M ⁷⁶	185	16	No	6MWD	6MWD improvement (+26 m at peak, +17 m at trough) TTCW not improved
	Orally*—Freedom C1 ⁷⁷	354	16	ERA and/or PDE-5i	6MWD	6MWD not improved TTCW not improved
	Orally*—Freedom C2 ⁷⁸	310	16	ERA and/or PDE-5i	6MWD	6MWD not improved TTC not improved
Inhaled Iloprost	AIR ⁷⁹	203	12	No	6MWD and FC	6MWD and WHO FC improved Haemodynamics improved at peak
	STEP ⁶⁶	67	12	Bosentan	6MWD	6MWD improved (p=0.05) TTCW improved
	COMBI ⁸⁰	40	12	Bosentan	6MWD (–)	Terminated for futility 6MWD not improved No clinical improvement
Beraprost*	ALPHABET ⁶⁹	130	12	No	6MWD	6MWD improved Haemodynamics not improved
Selexipag*	Phase 2 ⁷⁰	43	17	ERA and/or PDE-5i	PVR	PVR improved 6MWD not improved
	GRIPHON ⁷¹	1156	74	ERA and/or PDE-5i	TTCW	TTCW improved

Modified from Galie N *et al.*¹²

Note that most of the listed RCT data were derived from studies in adults with PAH. Healthcare providers must obtain valid information on the approval of any of the listed medications for use in paediatric PAH in the according country.

*This drug is not approved by the EMA at the time of submission of this manuscript.

6MWD, 6 min walk distance; CW, clinical worsening; ERA, European Medicines Agency; PAH, pulmonary arterial hypertension; PDE-5i, phosphodiesterase 5 inhibitor; RCT, randomised controlled trial; TTCW, time to clinical worsening.

without concomitant therapy was associated with sustained haemodynamic and clinical improvement, and an estimated 2-year survival of 91%.²⁵ However, at 4 years, disease progression in these patients on bosentan was high (54%), with a survival estimate of 82%.²⁷ More than 30 children (≥ 2 years and < 12 years old) were enrolled in the non-randomised FUTURE-1 study (n=36)²⁸ and its extension study, FUTURE-2 (33 children continued on bosentan therapy).²⁹ In the

FUTURE-2 study³⁰ (33 children, 2–11.9 years old; median exposure 28 months), adverse events (AEs) that were considered treatment-related occurred in 15 (41.7%) patients. Of 51 serious AEs, 3 were considered treatment-related: two incidences of reported PAH worsening and one of autoimmune hepatitis. Thus, in FUTURE-2, the paediatric bosentan formulation (dispersible tablets; 32 mg) was generally well tolerated, its safety profile comparable to that of the adult formulation when

Table 6 Characteristics of RCTs with PAH drugs testing upfront combination therapy

Drug(s) tested	Study	Patients number	Duration (weeks)	Background Therapy	Primary end point	Main results
Epoprostenol vs epoprostenol+bosentan	BREATHE-2 ⁸¹	33	12	No	PVR	PVR not improved 6MWD not improved
Bosentan, sildenafil, intravenous epoprostenol	Sitbon ⁸²	19	16	No	6MWD	6MWD improved
Ambrisentan or tadalafil vs ambrisentan+tadalafil	AMBITION ⁸³	500	78	No	TTCW	TTCW improved 6MWD improved
Ambrisentan+tadalafil	Hassoun ⁸⁴ (SSc only)	24	36	No	PVR RV mass (MRI)	PVR improved RV mass improved

Modified from Galie N *et al.*¹²

Note that most of the listed RCT data were derived from studies in adults with PAH. Healthcare providers must obtain valid information on the approval of any of the listed medications for use in paediatric PAH in the according country.

6MWD, 6 min walk distance; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; RCT, randomised controlled trial; RV, right ventricle; TTCW, time to clinical worsening; SSc, systemic sclerosis.

used in children, and the efficacy profile of bosentan similar to previous paediatric and adult PAH studies of shorter duration.³⁰ In adult PAH patients with Eisenmenger syndrome, bosentan improved exercise capacity and haemodynamics with few AEs, in the placebo-controlled BREATHE-5 trial²⁹ (figure 2, tables 2 and 3). Based on data of the BREATHE-3²⁶ (add-on bosentan to prostacyclin therapy in children) and FUTURE-1²⁸ studies, the paediatric formulation of bosentan was approved by the EMA for use in children with PAH older than 2 years of age, with a maximum target dose of 2 mg/kg body weight per dose daily (table 2). Recent safety data on the use of bosentan under 2 years of age are available through the FUTURE-3 study on the dosing interval in 64 PAH children from 3 months to 11 years of age. Subsequently, the EMA approved bosentan for the treatment of PAH in children starting from 1 year of age. Elevation of serum liver aminotransferases may occur as a serious AE during bosentan therapy, but was more frequent in adults and children ≥ 12 years of age (7.8%) than children under 12 years (2.7%) in an European Postmarketing Surveillance study.³¹ Nevertheless, it is recommended to perform liver function testing monthly in children receiving bosentan.

Ambrisentan

The ARIES-1 and ARIES-2 studies on ambrisentan, an oral selective ET_A-receptor antagonist, in adult PAH showed improvement of 6 min walk distance (6MWD) during the 12-week study periods (table 3). Subsequently, a retrospective cohort study on paediatric patients with PAH receiving ambrisentan as add-on therapy or transition from bosentan was conducted. In 38 children with PAH, ambrisentan transition or add-on therapy was associated with an improvement of WHO functional class in 31%. AEs such as headache were frequent, but no elevation of liver enzymes was observed.³²

Macitentan

Macitentan, a novel dual ERA, was developed by modifying the structure of bosentan to increase efficacy and safety. Macitentan has improved receptor binding capacity and has fewer drug-drug interactions compared with bosentan. The SERAPHIN study showed that macitentan significantly reduced a composite end point of morbidity and mortality in patients with PAH and also increased exercise capacity.³³ No liver toxicity was observed; however, a reduction in blood haemoglobin ≤ 8 g/dL was found in 4.3% of patients receiving 10 mg macitentan (table 3). In contrast to bosentan, macitentan does not appear to lower the plasma levels of sildenafil, although according specific studies are lacking. Today, no data on the use of macitentan in children are available.

Phosphodiesterase inhibitors (PDE-5i)

Sildenafil

Sildenafil is an orally active inhibitor of phosphodiesterase 5 (PDE-5, among other PDEs), inducing vasodilation and exhibiting antiproliferative effects through the NO/cGMP pathway within the pulmonary vasculature. RCTs in adult patients treated with sildenafil have confirmed favourable results on exercise capacity, symptoms and haemodynamics (table 4). STARTS-1³⁹ and STARTS-2⁴⁰ are the first paediatric randomised, placebo-controlled RCTs conducted in treatment-naïve children with PAH. In the STARTS-1 trial,³⁹ children with PAH 1–17 years old (≥ 8 kg body weight) received low-dose (10 mg), medium-dose (10–40 mg) or high-dose (20–80 mg) sildenafil or placebo orally three times daily for the duration of 16 weeks. There were no

statistically significant benefits for each sildenafil dosing group versus placebo in terms of the primary outcome measure, peak oxygen consumption (VO₂ max.), as assessed by cardiopulmonary exercise testing. However in the subgroup analysis, functional capacity significantly improved in the high-dose sildenafil-group, and PVR index was lowered with medium-dose and high-dose sildenafil. Unfortunately, there was a rise in mortality that was significantly higher in the high-dose sildenafil versus placebo group. These results led to different recommendations by the EMA and the FDA. In 2011, sildenafil received EMA approval for the use in children older than 1 year of age (10 mg three times daily for weight < 20 kg, and 20 mg three times daily for weight ≥ 20 kg). The higher mortality in the high-dose sildenafil group resulted in a warning of the EMA not to use higher doses in 2013. The FDA even released a warning against the (chronic) use of sildenafil in PAH children 1–17 years of age in 2013, which was clarified in 2014 ('no contraindication' for paediatric use of sildenafil). *Intravenous sildenafil* may play a role in children with persistent pulmonary hypertension of the newborn⁴¹ and postoperatively after congenital heart surgery;^{42 43} however, midsize, sufficiently powered, prospective studies have not been conducted yet.

Tadalafil

Tadalafil, an oral, selective PDE-5 inhibitor with a longer duration of action than sildenafil, was FDA-approved for use in adults with PAH in 2009. RCTs in adults showed an improvement in exercise capacity and quality of life with the administration of tadalafil (table 4). The use of tadalafil in children with PH has recently increased based on the results of a retrospective study (that suggested clinical efficacy and safety in children with PAH⁴⁴ and the above-mentioned FDA warning regarding the use of sildenafil). Still, there is no published RCT data on the use of tadalafil in paediatric PAH.

Guanylate cyclase stimulators

Riociguat

Riociguat, an oral agent with dual mode of action that acts in synergy with endogenous NO and also directly stimulates soluble guanylyl cyclase independent of NO availability is another promising therapy. In phase 3 trials on patients with symptomatic PAH (PATENT-1), riociguat therapy led to improved haemodynamics, functional class and time to clinical worsening.⁴⁵ Subsequently, a subgroup analysis of patients with persistent/recurrent PAH after repair of CHD (n=35) has been performed on the data sets of the PATENT studies.⁴⁶ Riociguat was well tolerated also in these PAH-CHD patients and improvement of clinical outcomes including 6MWD, PVR, WHO FC and NT-pro B-type natriuretic peptide were consistent with the drug effects in the overall population of PATENT-1 (table 4). An ongoing small trial will describe the use of riociguat in paediatric PAH and particularly its safety and potential adverse effects on bone/growth.

Vericiguat

A safety and efficacy phase 2 study on vericiguat (BAY1021189) in adult patients with heart failure and preserved ejection fraction is currently underway (<http://www.clinicaltrials.gov; NCT01951638>).

Prostacyclin analogues (PCA; prostaglandin I receptor agonists; IP receptor agonists)

Activation of the prostacyclin (PGI₂) receptor, IP receptor and prostanoid EP receptors by PGI₂ analogues induces vasodilation

in the pulmonary circulation, inhibits proliferation of vascular smooth muscle cells (anti-remodelling) and may have anti-inflammatory effects. Inhaled prostacyclin analogues (iloprost, treprostinil) is used in children with PAH, albeit as an off-label therapy, mostly as a sequential combination therapy with an ERA and/or PDE-5 inhibitor. In children and adolescents, particularly the required frequency of inhalations has a negative impact on patient compliance (6–8 times per 24 h for iloprost, 4–6 times per 24 h for treprostinil). In children with progressive, severe PAH (WHO functional class III or IV) and high predictive risk, inadequate response to combination therapy and/or clinical deterioration, (add-on) initiation of subcutaneous treprostinil, intravenous epoprostenol or intravenous treprostinil should be strongly considered (tables 1, 2, 5 and 6 and figures 2, 3).

Epoprostenol (intravenous infusion)

Epoprostenol was the first PGI₂ analogue and approved by the FDA for treatment of adults with PAH in 1995. Intravenous epoprostenol improves quality of life and survival in children and adults (non-composite primary outcome) with IPAH^{23 55 56} (table 5). In a retrospective analysis, children with IPAH who were treated with intravenous epoprostenol (n=24; AVT non-responders or those with CCB treatment failure) had a 4-year survival rate of 94%²³ and a 10-year freedom from death, transplantation or atrial septostomy (AS) of 37% (13/35).²² Combination of intravenous epoprostenol with oral sildenafil, bosentan or both was reported to result in better survival in an UK observational cohort of children with PAH.^{57 58} In children, the effective dose of epoprostenol appears to be higher than in adults. Uptitration of epoprostenol over time is common, but excessive doses (>120 ng/kg/min) may lead to high output states that require downtitration (table 2).⁵⁹ A new, more chemically stable epoprostenol preparation allows up to once-weekly preparation (up to eight cassettes at one time), which may not require ice packs or special mixing liquids (diluent). However, the short half-life of epoprostenol (2–5 min) keeps patients with PAH at very high risk for pulmonary vascular crisis when there is a sudden problem with drug delivery.

Treprostinil (subcutaneous infusion, intravenous infusion, intermittent inhalation)

Treprostinil is the tricyclic benzidine analogue of epoprostenol that is sufficiently stable to be given continuously per intravenous or subcutaneous route at room temperature in patients with PAH. The FDA approved treprostinil for subcutaneous use in 2002, for intravenous application in 2004 and for inhalative administration in 2009 (for adult PAH RCT results, see table 5). Subcutaneous use of continuous treprostinil via mini pumps is often associated with side pain but allows patients to live free of central venous catheters that inhere the possible complications of line infection, sudden occlusion or extravasal dislocation. Add-on subcutaneous treprostinil has been studied in eight children with PAH at an average dose of 40 ng/kg/min and tolerable side effects.⁶⁰ Highly efficient intravenous treprostinil can be given by continuous infusion through small, subcutaneous or external pumps, is mixed easily and has a much longer half-life (approximately 4 h) than epoprostenol (table 2). In adults with PAH, the dose of intravenous treprostinil appears to be 2–3 times higher than the dose of epoprostenol.⁶¹ A recent retrospective analysis of inhaled treprostinil administration in 29 children with PAH (3–9 breaths, 6 µg/breath, four times daily) showed promising results with an improvement in WHO functional class and 6MWD.⁶²

Iloprost (intermittent inhalation)

The PGI₂ analogue iloprost was approved for inhalative treatment of adults with PAH in the USA in 2004. Iloprost can be delivered by simple nebulisation in small children and by adaptive aerosol delivery in older children, adolescents and adults. Because of its short half-life, iloprost should be administered 6–9 times in 12–18 h (every 2–3 h, daily), requiring patient cooperation and solid patient compliance (tables 2 and 5).⁶³ In mid-2015, a new chip and higher concentrated ampoules were released in Europe, so that the inhalation times for iloprost can now be reduced from 10–15 to 5–8 min. The major advantage of inhaled prostacyclin are pulmonary vasodilation, and probably anti-inflammation and anti-remodelling effects, with usually little influence on systemic blood pressure. Headaches, jaw pain and airway reactivity⁶⁴ may occur at the beginning of iloprost therapy, so that preceding pulmonary function tests are recommended. Inhaled iloprost has been studied in combination with sildenafil⁶⁵ and bosentan⁶⁶ in adults, but phase 2/3 studies in children are lacking (table 5).

Beraprost (oral)

Beraprost is a prostacyclin analogue with a short half-life (40 min) that is not available in Europe and the USA, but approved in its long-acting form for PAH therapy in Japan and South Korea.⁶⁷ While short-term effects of beraprost have been described in adult PAH trials, the efficacy seemed to fade with longer treatment,^{68 69} and paediatric data on the efficacy of beraprost are limited to case reports.

Selexipag (oral)

Selexipag is an oral selective prostacyclin receptor (IP receptor) agonist. Its high functional selectivity for the IP receptor may help minimise gastric side effects. In a pilot RCT in patients with PAH receiving stable ERA and/or PDE-5 inhibitor therapy, selexipag reduced PVR after 17 weeks compared with placebo.⁷⁰ In the large PAH, event-driven, randomised, double-blind, placebo-controlled phase 3 trial on the efficacy of selexipag on the first morbidity and mortality event (GRIPHON; n=1156),⁷¹ selexipag significantly reduced the risk of morbidity/mortality events (composite primary end point: death from any cause or a complication related to PAH up to the end of the treatment period) versus placebo (log-rank p<0.0001) by 40% (HR 0.60; 99% CI 0.46 to 0.78; p<0.001). A primary end point event occurred in 397 patients – 41.6% of those in the placebo group and 27.0% of those in the selexipag group. Disease progression and hospitalisation accounted for 81.9% of the events. There was no significant difference in mortality between the two study groups.⁷¹ Oral selexipag may enable earlier combination drug therapy targeting the three-molecular pathways of PAH by combining oral dosing with higher IP receptor selectivity. A drug trial on the use of selexipag in children with PAH is expected to start soon.

Medication used in the intensive care unit (milrinone, levosimendan, inhaled nitric oxide)

Milrinone and levosimendan are lusitropic, positive inotropic agents typically considered for use in patients with PAH in WHO functional class IV. Milrinone, levosimendan and the potent local vasodilator, inhaled nitric oxide, are discussed in a separate article on the treatment of acute PAH in the intensive care unit.³

Combination pharmacotherapy in paediatric PAH

Children who deteriorate on either ERA or PDE-5 inhibitor agents may benefit from early dual or triple combination

Table 7 Potentially significant drug interactions with PAH targeted therapies

PAH drug	Mechanism of interaction	Interacting drug	Interaction
Ambrisentan	?	Cyclosporine ketoconazole	Caution is required in the coadministration of ambrisentan with ketoconazole and cyclosporine
Bosentan	CYP3A4 inducer	Sildenafil	Sildenafil levels fall 50%; bosentan levels increase 50%. May not require dose adjustments of either drug
	CYP3A4 substrate	Cyclosporine	Cyclosporine levels fall 50%; bosentan levels increase fourfold. Combination contraindicated
	CYP3A4 substrate	Erythromycin	Bosentan levels increase. May not require dose adjustment of bosentan during a short course
	CYP3A4 substrate	Ketoconazole	Bosentan levels increase twofold
	CYP3A4 substrate+bile salt pump inhibitor	Glibenclamide	Increase incidence of elevated aminotransferases. Potential decrease of hypoglycaemic effect of glibenclamide Combination contraindicated
	CYP2C9 and CYP3A4 substrate	Fluconazole, amiodarone	Bosentan levels increase considerably. Combination contraindicate
	CYP2C9 and CYP3A4 inducers	Rifampicin, phenytoin	Bosentan levels decrease by 58%. Need for dose adjustment uncertain
	CYP2C9 inducer	HMG CoA reductase inhibitors	Simvastatin levels reduce 50%; similar effects likely with atorvastatin. Cholesterol level should be monitored
	CYP2C9 inducer	Warfarin	Increases warfarin metabolism, may need to adjust warfarin dose. Intensified monitoring of warfarin recommended following initiation but dose adjustment usually unnecessary
	CYP2C9 and CYP3A4 inducers	Hormonal contraceptives	Hormone levels decrease. Contraception unreliable
Macitentan			To be determined
Selexipag			To be determined
Sildenafil ⁸⁵	CYP3A4 substrate	Bosentan	Sildenafil levels fall 50%; bosentan levels increase 50%. May not require dose adjustments of either drug
	CYP3A4 substrate	HMG CoA reductase inhibitors	May increase simvastatin/atorvastatin levels through competition for metabolism. Sildenafil levels may increase. Possible increased risk of rhabdomyolysis
	CYP3A4 substrate	HIV protease inhibitors	Ritonavir and saquinovir increase sildenafil levels markedly
	CYP3A4 inducer	Phenytoin	Sildenafil level may fall
	CYP3A4 substrate	Erythromycin	Sildenafil levels increase. May not require dose adjustment for a short course
	CYP3A4 substrate	Ketoconazole	Sildenafil levels increase. May not require dose adjustment
	CYP3A4 substrate	Cimetidine	Sildenafil levels increase. May not require dose adjustment
	cGMP	Nitrates Nicorandil Molsidomine	Profound systemic hypotension, combination contraindicated
Tadalafil ⁸⁶	CYP3A4 substrate	Bosentan	Tadalafil exposure decreases by 42%, no significant changes in bosentan levels. ⁴⁴ May not require dose adjustment
	cGMP	Nitrates Nicorandil	Profound systemic hypotension, combination contraindicated
Riociguat ⁴⁷	cGMP	Sildenafil	Hypotension, severe side effects, combination contraindicated
	cGMP	Nitrates Nicorandil	Profound systemic hypotension

Adapted from National Pulmonary Hypertension Centres of the UK and Ireland.⁸⁷

Note that most of the listed RCT data were derived from studies in adults with PAH. Healthcare providers must obtain valid information on the approval of any of the listed medications for use in paediatric PAH in the according country.

cGMP, cyclic guanosine monophosphate; PAH, pulmonary arterial hypertension; RCT, randomised controlled trial.

therapy. Combination therapy (early combination or rapid sequence/add-on) versus monotherapy has not been studied in children yet. Prospective studies are needed to help establish any solid recommendations for combination therapy in children with PH. A modified algorithm on combination therapy based on the adult 2015 ESC/ERS guidelines for PH¹² is given in [figure 3](#).

Characteristics and major findings of RCTs testing upfront combination therapy in adult PAH are shown in [table 6](#).

Drug interactions

The potentially significant drug interactions with PAH-targeted therapies are listed in [table 7](#).

Experimental compounds and strategies

Because of the lack of any validated prospective paediatric data or even drug approval in childhood, the above-

mentioned compounds macitentan, tadalafil, riociguat, vericiguat, beraprost and selexipag must be considered experimental paediatric PH pharmacotherapy ('compassionate use') until convincing clinical data become available. Venoarterial-ECMO as bridge to lung transplantation or bridge to recovery in severe PAH is discussed in a separate article of the European Paediatric Pulmonary Vascular Disease Network.³ A limited number of studies on the value of balloon atrial septostomy (AS) and Potts shunt in advanced paediatric PAH are available and will be discussed in the following section.

Catheter-based and surgical therapy of advanced PAH

To avoid overt right heart failure in patients with severe and refractory PAH, a right-to-left shunt can be created with the aim

to decompress right heart structures and to increase and maintain cardiac output. With these interventions, a haemodynamic situation occurs, which is similar to the physiology of Eisenmenger patients, whose RV systolic function is preserved longer, and who have somewhat better survival than IPAH patients without a decompressing shunt.⁸⁸ Treatment of PAH associated with CHD is discussed in a separate article of the European Paediatric PVD Network.⁴

Atrial septostomy

Atrial septostomy (AS) is the most frequently applied interventional technique that is used as a palliative therapy in the management of patients with advanced PH and failing RV⁸⁹ when medical therapy has failed. AS improves symptoms and quality of life in paediatric PAH and may serve as bridge to lung transplantation. Following puncture of the interatrial septum in Brockenbrough technique, the defect is stepwise balloon-dilated until the predetermined diameter is achieved or the arterial oxygen saturation has dropped 10% from baseline. As spontaneous closure of the created defect occurs in almost 10%, the procedure may be repeated and/or a stent device can be implanted to keep the communication patent.

According to a 2009 worldwide retrospective analysis of 223 patients including a significant number of children, procedure-related mortality was very high (7.1% at 24 h and 14.8% at 1 month),⁹⁰ while immediate and long-term haemodynamic response including survival (available in 128 patients) was encouraging with a median survival of 60 months.⁹⁰

However, more recent studies suggest that AS can be a safe procedure in selected patients with PAH when performed in expert centres, and that AS in combination with PAH-targeted therapy improves survival: a recent retrospective study from Mexico analysed the clinical impact of AS in treatment-naïve patients with severe PAH (age range 22–62 years, 85% IPAH: 21 underwent AS alone, 11 received additional drug therapy).⁹¹ There was one procedure-related death in 50 procedures performed on 32 patients. Median survival was 53 months in the AS-alone group and 83 months in the AS+PAH-targeted therapy group.⁹¹ In a recent retrospective analysis of 46 AS procedures performed in 32 paediatric/adult patients with PAH (69% in WHO FC III or IV) in a high-volume PH centre in New York between 2002 and 2013, there were no procedural complications or deaths. Seven of 32 patients were successfully bridged to lung transplantation. Lung transplantation-free and repeat-AS-free survival at 30 days, 1 year and 5 years was 87%, 61% and 32%, respectively.⁹²

Based on the risk factors found in the international study with high procedure-related mortality,⁹⁰ *contraindications for AS* include (1) a mean right atrial pressure of >20 mm Hg, (2) resting arterial oxygen saturation <90%, (3) severe RV failure and (4) patients with impending death. AS can be considered in patients in functional class III and IV and recurrent syncope under combined medical therapy, and as palliative bridge to transplant increasing the chance for survival while waiting for a donor organ.^{92–93}

Potts shunt (LPA-DAO)

This surgical procedure implies the creation of a connection between the left pulmonary artery (LPA) and the descending aorta (DAO), which allows right-to-left shunting, similarly to a patient with a patent ductus arteriosus-related Eisenmenger syndrome. The use of a Potts (LPA-DAO) shunt in suprasystemic PH is considered advantageous compared with AS as it provides high oxygen saturated blood for the coronary arteries and the central

nervous system and only causes desaturation of the lower body. In addition, the risk of fatal paradoxical embolisms may be lower compared with a connection on the atrial level. Another benefit arises from its effect on haemodynamics by the relief of RV pressure overload in systole and, in part, also in diastole with a subsequent reduction in shifting of the interventricular septum towards the LV with an improvement in systolic and diastolic LV performance. The connection between the pulmonary artery and the descending aorta can be achieved either by a direct side-by-side anastomosis or by using a synthetic graft tube/prosthesis, which should have the size of the descending aorta to allow sufficient decompression of the RV. A run-off through the Potts shunt with decreased pulmonary perfusion and extreme desaturation of the lower body with subsequent undersupply of the myocardium and the brain should be avoided.

Given that the experience with the Potts shunt procedure is nearly exclusively available in children, these data cannot be extrapolated to severely ill adults, which may have a considerably higher periprocedural risk. The procedure may be considered in patients with suprasystemic PH refractory to any medical treatment including combined therapy presenting in New York Heart Association/WHO functional class IV.

The largest series published by Baruteau and colleagues consisted of 24 children with drug-refractory PAH in which a permanent Potts shunt was created (19 surgical LPA-DAO, 6 via stenting of a persistent ductus arteriosus (PDA)).⁹⁴ Six patients experienced severe postoperative complications and three early deaths relating to low cardiac output occurred. After a median follow-up of 2.1 years, the 21 survivors showed persistent improvement in functional capacities, and none of the patients had syncope or overt RV failure.⁹⁴ These favourable long-term results suggest that creation of a Potts shunt can be a valuable alternative, or bridge to bilateral lung transplantation, at least in selected cases.

Recently, several case series demonstrated the feasibility of the pure catheter-based interventional implementation of the connection between the left PA and the descending aorta.^{95–98} The obviously most elegant method is the implantation of a stent in a still patent PDA, which is not infrequently present in infants and young children.^{95–97} This procedure is an established method in CHD with duct-dependent circulation and can be established with considerable low periprocedural risk in experienced centres. Currently, the interventional de novo creation of a LPA-DAO connection with a covered stent from the LPA⁹⁶ or DAO side⁹⁸ has been shown to be feasible but currently must be considered a high-risk procedure in patients with end-stage PAH who are too sick to undergo surgery.

Pulmonary artery denervation

The rationale for the pulmonary artery denervation (PADN) procedure is based on the observation that baroreceptors and sympathetic nerve fibres are localised in or near the bifurcation of the main pulmonary artery. Two small pilot studies demonstrated some benefits of PADN on exercise capacity and symptoms of patients with adult PAH at 3 and 12 months follow-up.^{99–100} Data on the safety and efficacy of PADN in children with PAH are lacking.

CHALLENGES IN CLINICAL STUDIES OF PAEDIATRIC PAH

1. Identification of valid treatment goals in paediatric PAH.^{101–102}
2. Regulatory requirements, patient recruitment and retention, clinical trial end points for paediatric PAH trials.¹⁰²

3. Need for interdisciplinary, international PVD networks to conduct multicentre studies and to establish registries. ^{103 104}
4. Initiation of a prospective multicenter study on early combination therapy in paediatric PH including a comparative group (early combined dual or triple combination, rapid sequence of two agents).
5. When and how to perform a Potts shunt procedure for advanced PAH (surgery, intervention?) and how to combine this pressure-unloading shunt with combination pharmacotherapy?
6. Initiation of investigator-initiated pilot and/or industry-sponsored phase 2–4 studies on the safety and efficacy of new compounds recently published/approved for adult PAH (macitentan, riociguat, selexipag, treprostinil).

Author affiliations

¹Department of Paediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany

²Division of Paediatric Cardiology, Children's University Hospital Ulm, Ulm, Germany

Acknowledgements The authors thank Damien Bonnet, Paris, for critically reviewing this manuscript and this manuscript, and Cengiz Tamak, Hannover, for editorial assistance.

Funding GH currently receives grant support from the German Research Foundation (DFG; HA 4348/2-1), Kinderherzen e.V. (W-H-001-2014), and Stiftung Kinderherz (2511-6-13-011). CA currently receives grant funding from Stiftung Kinderherz (2511-10-13-001) and Behring-Röntgen-Stiftung (59-0018).

This *Heart* supplement was produced with support from an unrestricted educational grant from Actelion Pharmaceuticals Germany GmbH, Bayer Pharma AG, and Pfizer Inc. None of these organisations had any influence on the composition of the writing group or the content of the articles published in this supplement. Open Access publication of this article was sponsored by Actelion Pharmaceuticals Germany GmbH.

Competing interests GH and CA declare no conflict of interest.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- 1 D'Alonzo GE, Barst RJ, Ayres SM, *et al.* Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med* 1991;115:343–9.
- 2 Hansmann G, Apitz C, Abdul-Khaliq H, *et al.* Executive Summary. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart* 2016;102:ii86–100.
- 3 Kaestner M, Schranz D, Warnecke G, *et al.* Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart* 2016;102:ii57–66.
- 4 Kozlik-Feldmann R, Hansmann G, Bonnet D, *et al.* Pulmonary Hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart* 2016;102:ii42–8.
- 5 Hilgendorff A, Apitz C, Bonnet D, *et al.* Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart* 2016;102:ii49–56.
- 6 McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. *Circulation* 2006;114:1417–31.
- 7 Ivy DD, Abman SH, Barst RJ, *et al.* Paediatric pulmonary hypertension. *J Am Coll Cardiol* 2013;62(25 Suppl):D117–26.
- 8 Sandoval J, Aguirre JS, Pulido T, *et al.* Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. *Am J Respir Crit Care Med* 2001;164:1682–7.
- 9 Rich S, Seidlitz M, Dodin E, *et al.* The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. *Chest* 1998;114:787–92.
- 10 Maron BA, Waxman AB, Opatowsky AR, *et al.* Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). *Am J Cardiol* 2013;112:720–5.
- 11 Calvier L, Legchenko E, L. G, *et al.* Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension. *Heart* 2016;102:390–6.
- 12 Galiè N, Humbert M, Vachiery JL, *et al.* 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 2015;37:67–119.
- 13 Barst RJ, Rubin LJ, Long WA, *et al.* A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med* 1996;334:296–301.
- 14 Sandoval J, Santos LE, Córdova J, *et al.* Does anticoagulation in Eisenmenger syndrome impact long-term survival? *Congenit Heart Dis* 2012;7:268–76.
- 15 Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. *Am J Gastroenterol* 2000;95:415–18.
- 16 Lammers AE, Apitz C, Zartner P, *et al.* Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/ paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart* 2016;102:ii1–13.
- 17 Apitz C, Hansmann G, Schranz D. Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. *Heart* 2016;102:ii23–9.
- 18 Barst RJ, Agnoletti G, Fraisse A, *et al.* Vasodilator testing with nitric oxide and/or oxygen in paediatric pulmonary hypertension. *Pediatr Cardiol* 2010;31:598–606.
- 19 Montani D, Savale L, Natali D, *et al.* Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. *Eur Heart J* 2010;31:1898–907.
- 20 Douwes JM, Roofthoof MT, Van Loon RL, *et al.* Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. *Heart* 2014;100:224–30.
- 21 Barst RJ, McGoon MD, Elliott CG, *et al.* Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. *Circulation* 2012;125:113–22.
- 22 Yung D, Widlitz AC, Rosenzweig EB, *et al.* Outcomes in children with idiopathic pulmonary arterial hypertension. *Circulation* 2004;110:660–5.
- 23 Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. *Circulation* 1999;99:1197–208.
- 24 Galiè N, Ussia G, Passarelli P, *et al.* Role of pharmacologic tests in the treatment of primary pulmonary hypertension. *Am J Cardiol* 1995;75:55A–62A.
- 25 Rosenzweig EB, Ivy DD, Widlitz A, *et al.* Effects of long-term bosentan in children with pulmonary arterial hypertension. *J Am Coll Cardiol* 2005;46:697–704.
- 26 Barst RJ, Ivy D, Dingemans J, *et al.* Pharmacokinetics, safety, and efficacy of bosentan in paediatric patients with pulmonary arterial hypertension. *Clin Pharmacol Ther* 2003;73:372–82.
- 27 Ivy DD, Rosenzweig EB, Lemarié JC, *et al.* Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. *Am J Cardiol* 2010;106:1332–8.
- 28 Beghetti M, Haworth SG, Bonnet D, *et al.* Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. *Br J Clin Pharmacol* 2009;68:948–55.
- 29 Galiè N, Beghetti M, Gatzoulis MA, *et al.* Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. *Circulation* 2006;114:48–54.
- 30 Berger RM, Haworth SG, Bonnet D, *et al.* FUTURE-2: results from an open-label, long-term safety and tolerability extension study using the paediatric Formulation of bosentan in pUlmonary arterial hypeRtEnsiOn. *Int J Cardiol* 2016;202:52–8.
- 31 Beghetti M, Hoepfer MM, Kiely DG, *et al.* Safety experience with bosentan in 146 children 2–11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. *Pediatr Res* 2008;64:200–4.
- 32 Takatsuki S, Rosenzweig EB, Zuckerman W, *et al.* Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. *Pediatr Pulmonol* 2013;48:27–34.
- 33 Pulido T, Adzerikho I, Channick RN, *et al.* Macitentan and morbidity and mortality in pulmonary arterial hypertension. *N Engl J Med* 2013;369:809–18.
- 34 Galiè N, Olschewski H, Oudiz RJ, *et al.* Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation* 2008;117:3010–19.

- 35 Channick R, Badesch DB, Tapson VF, *et al.* Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. *J Heart Lung Transplant* 2001;20:262–3.
- 36 Rubin LJ, Badesch DB, Barst RJ, *et al.* Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med* 2002;346:896–903.
- 37 Galiè N, Rubin L, Hoeper M, *et al.* Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. *Lancet* 2008;371:2093–100.
- 38 McLaughlin V, Channick RN, Ghofrani HA, *et al.* Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. *Eur Respir J* 2015;46:405–13.
- 39 Barst RJ, Ivy DD, Gaitan G, *et al.* A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary arterial hypertension. *Circulation* 2012;125:324–34.
- 40 Barst RJ, Beghetti M, Pulido T, *et al.* STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naïve paediatric pulmonary arterial hypertension. *Circulation* 2014;129:1914–23.
- 41 Steinhorn RH, Kinsella JP, Pierce C, *et al.* Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. *J Pediatr* 2009;155:841–7.e1.
- 42 Fraisse A, Butrous G, Taylor MB, *et al.* Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. *Intensive Care Med* 2011;37:502–9.
- 43 Sharma VK, Joshi S, Joshi A, *et al.* Does intravenous sildenafil clinically ameliorate pulmonary hypertension during perioperative management of congenital heart diseases in children?—A prospective randomized study. *Ann Card Anaesth* 2015;18:510–16.
- 44 Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in paediatric pulmonary arterial hypertension. *Pediatr Cardiol* 2012;33:683–8.
- 45 Ghofrani HA, Galiè N, Grimminger F, *et al.* Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med* 2013;369:330–40.
- 46 Rosenkranz S, Ghofrani HA, Beghetti M, *et al.* Riociguat for pulmonary arterial hypertension associated with congenital heart disease. *Heart* 2015;101:1792–9.
- 47 Galiè N, Muller K, Scalise AV, *et al.* PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. *Eur Respir J* 2015;45:1314–22.
- 48 Galiè N, Ghofrani HA, Torbicki A, *et al.* Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med* 2005;353:2148–57.
- 49 Sastry BK, Narasimhan C, Reddy NK, *et al.* Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. *J Am Coll Cardiol* 2004;43:1149–53.
- 50 Singh TP, Rohit M, Grover A, *et al.* A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. *Am Heart J* 2006;151:851.e1–5.
- 51 Simonneau G, Rubin LJ, Galiè N, *et al.* Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med* 2008;149:521–30.
- 52 Iversen K, Jensen AS, Jensen TV, *et al.* Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. *Eur Respir J* 2010;31:1124–31.
- 53 Galiè N, Brundage BH, Ghofrani HA, *et al.* Tadalafil therapy for pulmonary arterial hypertension. *Circulation* 2009;119:2894–903.
- 54 Jing ZC, Yu ZX, Shen JY, *et al.* Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. *Am J Respir Crit Care Med* 2011;183:1723–9.
- 55 Barst RJ, Rubin LJ, McGoon MD, *et al.* Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. *Ann Intern Med* 1994;121:409–15.
- 56 Nakayama T, Shimada H, Takatsuki S, *et al.* Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. *Circ J* 2007;71:1785–90.
- 57 Moledina S, Hislop AA, Foster H, *et al.* Childhood idiopathic pulmonary arterial hypertension: a national cohort study. *Heart* 2010;96:1401–6.
- 58 Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006. *Heart* 2009;95:312–17.
- 59 Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. *J Am Coll Cardiol* 1999;34:1184–7.
- 60 Levy M, Celermeier DS, Bourges-Petit E, *et al.* Add-on therapy with subcutaneous treprostinil for refractory paediatric pulmonary hypertension. *J Pediatr* 2011;158:584–8.
- 61 Sitbon O, Manes A, Jais X, *et al.* Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. *J Cardiovasc Pharmacol* 2007;49:1–5.
- 62 Krishnan U, Takatsuki S, Ivy DD, *et al.* Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. *Am J Cardiol* 2012;110:1704–9.
- 63 Olschewski H, Hoeper MM, Behr J, *et al.* Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. *Respir Med* 2010;104:731–40.
- 64 Ivy DD, Doran AK, Smith KJ, *et al.* Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. *J Am Coll Cardiol* 2008;51:161–9.
- 65 Ghofrani HA, Wiedemann R, Rose F, *et al.* Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. *Ann Intern Med* 2002;136:515–22.
- 66 McLaughlin VV, Oudiz RJ, Frost A, *et al.* Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2006;174:1257–63.
- 67 Kunieda T, Nakanishi N, Matsubara H, *et al.* Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. *Int Heart J* 2009;50:513–29.
- 68 Barst RJ, McGoon M, McLaughlin V, *et al.* Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol* 2003;41:2119–25.
- 69 Galiè N, Humbert M, Vachiery JL, *et al.* Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol* 2002;39:1496–502.
- 70 Simonneau G, Torbicki A, Hoeper MM, *et al.* Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. *Eur Respir J* 2012;40:874–80.
- 71 Sitbon O, Channick R, Chin KM, *et al.* Selexipag for the treatment of pulmonary arterial hypertension. *N Engl J Med* 2015;373:2522–33.
- 72 Rubin LJ, Mendoza J, Hood M, *et al.* Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. *Ann Intern Med* 1990;112:485–91.
- 73 Badesch DB, Tapson VF, McGoon MD, *et al.* Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med* 2000;132:425–34.
- 74 Simonneau G, Barst RJ, Galiè N, *et al.* Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med* 2002;165:800–4.
- 75 McLaughlin VV, Benza RL, Rubin LJ, *et al.* Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol* 2010;55:1915–22.
- 76 Jing ZC, Parikh K, Pulido T, *et al.* Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. *Circulation* 2013;127:624–33.
- 77 Tapson VF, Torres F, Kermeen F, *et al.* Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. *Chest* 2012;142:1383–90.
- 78 Tapson VF, Jing ZC, Xu KF, *et al.* Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. *Chest* 2013;144:952–8.
- 79 Olschewski H, Simonneau G, Galiè N, *et al.* Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med* 2002;347:322–9.
- 80 Hoeper MM, Leuchte H, Halank M, *et al.* Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J* 2006;28:691–4.
- 81 Humbert M, Barst RJ, Robbins IM, *et al.* Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J* 2004;24:353–9.
- 82 Sitbon O, Jais X, Savale L, *et al.* Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. *Eur Respir J* 2014;43:1691–7.
- 83 Galiè N, Barberà JA, Frost A, *et al.* Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. *New Engl J Med* 2015;373:834–44.
- 84 Hassoun PM, Zamanian RT, Damico R, *et al.* Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2015;192:1102–10.
- 85 Paul GA, Gibbs JS, Boobis AR, *et al.* Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. *Br J Clin Pharmacol* 2005;60:107–12.
- 86 Wrishko RE, Dingemans J, Yu A, *et al.* Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. *J Clin Pharmacol* 2008;48:610–8.
- 87 National Pulmonary Hypertension Centres of the UK, Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. *Heart* 2008;94(Suppl 1):i1–41.
- 88 Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. *Am J Cardiol* 2002;89:34–8.
- 89 Lammers AE, Haworth SG, Diller GP. Atrial septostomy in patients with pulmonary hypertension: should it be recommended? *Expert Rev Respir Med* 2011;5:363–76.

- 90 Keogh AM, Mayer E, Benza RL, *et al.* Interventional and surgical modalities of treatment in pulmonary hypertension. *J Am Coll Cardiol* 2009;54:S67–77.
- 91 Sandoval J, Gaspar J, Pena H, *et al.* Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. *Eur Respir J* 2011;38:1343–8.
- 92 Chiu JS, Zuckerman WA, Turner ME, *et al.* Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes. *J Heart Lung Transplant* 2015;34:376–80.
- 93 Law MA, Grifka RG, Mullins CE, *et al.* Atrial septostomy improves survival in select patients with pulmonary hypertension. *Am Heart J* 2007;153:779–84.
- 94 Baruteau AE, Belli E, Boudjemline Y, *et al.* Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. *Eur J Cardiothorac Surg* 2015;47:e105–10.
- 95 Boudjemline Y, Patel M, Malekzadeh-Milani S, *et al.* Patent ductus arteriosus stenting (transcatheter Potts shunt) for palliation of suprasystemic pulmonary arterial hypertension: a case series. *Circ Cardiovasc Interv* 2013;6:e18–20.
- 96 Esch JJ, Shah PB, Cockrill BA, *et al.* Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. *J Heart Lung Transplant* 2013;32:381–7.
- 97 Latus H, Apitz C, Moysich A, *et al.* Creation of a functional Potts shunt by stenting the persistent arterial duct in newborns and infants with suprasystemic pulmonary hypertension of various etiologies. *J Heart Lung Transplant* 2014;33:542–6.
- 98 Schranz D, Kerst G, Menges T, *et al.* Transcatheter creation of a reverse Potts shunt in a patient with severe pulmonary arterial hypertension associated with Moyamoya syndrome. *EuroIntervention* 2015;11:121.
- 99 Chen SL, Zhang FF, Xu J, *et al.* Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). *J Am Coll Cardiol* 2013;62:1092–100.
- 100 Chen SL, Zhang H, Xie DJ, *et al.* Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the pulmonary artery denervation-1 study. *Circ Cardiovasc Interv* 2015;8:e002837.
- 101 Ploegstra MJ, Douwes JM, Roofthoof MT, *et al.* Identification of treatment goals in paediatric pulmonary arterial hypertension. *Eur Respir J* 2014;44:1616–26.
- 102 Beghetti M, Berger RM. The challenges in paediatric pulmonary arterial hypertension. *Eur Respir Rev* 2014;23:498–504.
- 103 Hansmann G. Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from paediatric oncologists. *Pulm Circ* 2013;3:792–801.
- 104 Hansmann G, Hoeper MM. Registries for paediatric pulmonary hypertension. *Eur Respir J* 2013;42:580–3.